A Prospective, Multi-national, Multi-center, Double-blind, Randomized, Active Controlled, Parallel-group, Seamless Phase II/III Clinical Study to Evaluate the Safety and Immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' Compared With 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in Healthy Infants
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Poliovirus vaccine inactivated (Primary)
- Indications Poliomyelitis
- Focus Pharmacodynamics
- Sponsors LG Chem; LG Life Sciences
- 15 Jan 2019 Planned End Date changed from 31 May 2019 to 30 Jun 2019.
- 15 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Jan 2019.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.